R&D channel feed

Q2 ven­ture in­vest­ing slows a tad, but the big mon­ey still flows in­to biotech

9 years ago
Financing

CAR-T play­er Juno grabs a PhII com­bo drug in $10M add-on deal

9 years ago

Kad­mon sticks a $100M toe in chilly mar­ket wa­ters

9 years ago

San­thera’s Duchenne drug hits a road­block at the FDA, and one an­a­lyst sees an­oth­er bad sign for Sarep­ta

9 years ago

And then there were 4: Juno adds an­oth­er vic­tim in CAR-T death tal­ly

9 years ago

Po­laris is piec­ing to­geth­er a new, $400M-plus biotech fund as good times roll

9 years ago

Biosim­i­lars go 2-0 in an FDA dou­ble-head­er fa­vor­ing No­var­tis, Am­gen

9 years ago

The 15 top R&D spenders in the glob­al bio­phar­ma busi­ness: 2016

9 years ago
Special

Mer­ck vet Michael Rosen­blatt joins R&D ex­o­dus to the start­up world

9 years ago

Periscope: Un­suc­cess­ful on Nas­daq, Gen­Sight finds a home on Paris ex­change

9 years ago

In a stun­ner, FDA im­me­di­ate­ly drops its hold on Juno’s lead CAR-T

9 years ago

Mer­ck trig­gers a new round of lay­offs in R&D re­or­ga­ni­za­tion, push­ing more jobs in­to Cam­bridge, San Fran­cis­co

9 years ago

Sage claims an­oth­er big win on a small study, this time for post­par­tum de­pres­sion

9 years ago

$42M in, Flag­ship star­tups merge in­to one im­muno-mi­cro­bio­me plat­form with mul­ti­ple tar­gets

9 years ago
Startups

Shire gains a de­layed FDA OK for ‘block­buster’ dry eye drug li­fite­grast

9 years ago

CytRx con­cedes that its on­ly drug flunked a PhI­II sar­co­ma test, rout­ing shares

9 years ago

Periscope: Ex-Bax­al­ta ex­ec David Meek takes Paris-based helm for Ipsen

9 years ago

I/O en­thu­si­ast Servi­er signs up for an $807M, sec­ond wave PD-1 de­vel­op­ment deal with Sor­ren­to

9 years ago

Su­cam­po shut­ters de­vel­op­ment ef­fort af­ter lead drug flops in back-to-back stud­ies

9 years ago

FDA of­fers No­var­tis a thumbs-up on En­brel biosim­i­lar as Am­gen plays of­fense/de­fense si­mul­ta­ne­ous­ly

9 years ago

Celyad bounces back from heart study flop to ink a $312M I/O deal with Ono

9 years ago

Juno scram­bles to avoid be­ing crushed by a hold, but ex­perts ques­tion its best case sce­nario

9 years ago

Glax­o­SmithK­line cau­tious­ly fol­lows Sanofi, ramps up a new project for Zi­ka with the NIH

9 years ago

Am­gen tees up a swift ap­proval for a fran­chise de­stroy­er aimed at Ab­b­Vie’s $14B drug Hu­mi­ra

9 years ago
First page Previous page 328329330331332333 Next page Last page
A service from the Financial Times